-
Sector Analysis
NewCell and Gene Therapies in CNS Disorders – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies in CNS Disorders Market Report Overview The cell and gene therapies (CGT) sales in central nervous system (CNS) disorders was $1.5 billion in 2023. It will experience significant growth, achieving a CAGR of more than 42% during the forecast period. Gene therapies will dominate the CGT market in CNS disorders because of strong players such as Sarepta Therapeutics and Novartis with marketed products Elevidys and Zolgensma, respectively. Cell and Gene Therapies in CNS Disorders Market Outlook...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dilanubicel in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dilanubicel in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dilanubicel in Acute Lymphocytic Leukemia (ALL,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dilanubicel in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dilanubicel in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dilanubicel in Chronic Myelocytic Leukemia (CML,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SER-155 in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SER-155 in Graft Versus Host Disease (GVHD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SER-155 in Graft Versus Host Disease (GVHD) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NNV1 in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NNV1 in Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NNV1 in Glioblastoma Multiforme (GBM) Drug Details: NNV1 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TSC-100 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TSC-100 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TSC-100 in Acute Lymphocytic Leukemia (ALL, Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TSC-100 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TSC-100 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TSC-100 in Acute Myelocytic Leukemia (AML, Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TSC-100 in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TSC-100 in Myelodysplastic Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TSC-100 in Myelodysplastic Syndrome Drug Details: TSC-100 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Letermovir in Human Immunodeficiency Virus (HIV) Infections (AIDS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Letermovir in Human Immunodeficiency Virus (HIV) Infections (AIDS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Letermovir in Human Immunodeficiency Virus (HIV) Infections...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Adipose Tissue Derived Mesenchymal Stromal/Stem Cells in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Adipose Tissue Derived Mesenchymal Stromal/Stem Cells in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Adipose Tissue Derived Mesenchymal Stromal/Stem...